SLC5A2 and Stroke: Similarly, the SGLT2-inhibitor group revealed a significantly lower cumulative incidence rate of developing stroke than the non-SGLT2-inhibitor group as per the Kaplan–Meier survival analysis (P < 0.0001, Figure 2B).